Substituted Benzenecarboxamides for IL-17A Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for the development of small molecule modulators of IL-17A to treat various diseases associated with increased levels of this pro-inflammatory cytokine, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and certain cancers, as existing modulators are limited.
Innovation Solution
Development of substituted benzenecarboxamide compounds represented by Formula I, which can act as IL-17A modulators, potentially inhibiting its activity and mitigating inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule modulators of IL-17A are developed to treat inflammatory diseases, then therapeutic effectiveness is improved, but the complexity of drug discovery and development increases
Solution Approach 1:
The patent segments the IL-17A modulator development into specific chemical series (benzenecarboxamide compounds with particular structural features), allowing systematic exploration of structure-activity relationships within defined molecular frameworks rather than searching the entire chemical space
Solution Approach 2:
The patent systematically varies specific molecular parameters (substituents at defined positions on the benzenecarboxamide core structure) to optimize IL-17A binding affinity and selectivity, enabling rational drug design based on identified structure-activity relationships
2Object-generated harmful factors
If IL-17A activity is strongly inhibited to treat autoimmune diseases, then inflammatory response is reduced, but immune defense against microbes may be compromised
Solution Approach 1:
The patent designs compounds with specific local structural features (particular substituent patterns on the benzenecarboxamide core) that target IL-17A signaling pathways involved in autoimmune inflammation while potentially sparing microbial defense functions, achieving selective modulation of different IL-17A-dependent immune responses
Data Source
AI summary
The disclosure herein provides compounds and pharmaceutical compositions of the structure of the following formula:for the modulation of IL-17A. useful for the treatment of inflammatory conditions, such as psoriasis.